ArticleAnnals of gastroenterology

Combination therapy is not associated with improved rates of clinical or endoscopic remission in patients with inflammatory bowel disease treated with ustekinumab or vedolizumab: a retrospective study.

Angus W Jeffrey et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.